# US 2024/0390385 A1 · Composition and Methods for the Prevention of Aminoglycoside Toxicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390385 A1
- Document ID: US20240390385A1
- Status: Published application
- Kind: A1
- Application number: 18/792,993
- Filed: 2024-08-02
- Published: 2024-11-28
- Earliest claimed: 2020-09-15
- Assignees: Ting Therapeutics LLC
- Applicants: Ting Therapeutics LLC
- Inventors: Jian Zuo; Marisa Laura Zallocchi
- Web page: https://patentgrep.com/patent/US20240390385A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/16: Otologicals
- C07D 205/08: with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D 207/267: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
- C07D 211/76: attached in position 2 or 6
- C07D 223/10: attached in position 2
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to therapeutic uses of active agents such as for treating, inhibiting, and/or preventing damage associated with aminoglycoside toxicity. The data establishes that piperlongumine can protect hair cells from aminoglycoside damage within a wide range of concentrations. The range is 0.1 pM to 25 uM. Furthermore, piperlongumine protects renal function, it has a good therapeutic index (TI>200,000), no interference with AG's anti-bacterial activity, and no drug-drug interaction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A method to prevent aminoglycoside toxicity comprising systemically co-administering to an animal or human, an aminoglycoside and an effective amount of piperlongumine to prevent aminoglycoside toxicity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aminoglycoside toxicity affects ear hair cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the aminoglycoside toxicity affects renal function.

### Claim 4 (depends on 2)

The method of claim 2, wherein the concentration of the piperlongumine ranges from 0.1 pM to 25 uM.

### Claim 5

A method of preventing aminoglycoside toxicity, the method comprising administering a therapeutically effective amount of an active agent to downregulate TRPV1, or a pharmaceutically acceptable salt thereof and an aminoglycoside, wherein the active agent is selected from the group consisting of: piperlongumine; a derivative of piperlongumine or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the aminoglycoside toxicity affects ear hair cells.

### Claim 7 (depends on 5)

The method of claim 5, wherein the aminoglycoside toxicity affects renal function.

### Claim 8 (depends on 5)

The method of claim 5, wherein the concentration of the active agent ranges from 0.1 pM to 25 uM.

### Claim 9

A formulation for systemic administration to a subject comprising: an effective amount a derivative of piperlongumine to prevent aminoglycoside toxicity in a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The formulation of claim 9, wherein the derivative of piperlongumine is comprised of the formula:

### Claim 11 (depends on 9)

The formulation of claim 9, wherein the derivative of piperlongumine is comprised of the formula:

### Claim 12 (depends on 9)

The formulation of claim 9, wherein the derivative of piperlongumine is comprised of the formula (C16H15F2NO4):

### Claim 13 (depends on 9)

The formulation of claim 9, wherein the derivative of piperlongumine (PG 54 (SHJ-54)) is comprised of the formula (C15H13F2NO4):

### Claim 14

A kit comprising: an active agent, wherein the active agent is piperlongumine, a derivative of piperlongumine, or a pharmaceutically acceptable salt thereof; and one or more of:
at least one antibiotic; or
at least one cancer drug; and
instructions for preventing a hearing impairment.

### Claim 15 (depends on 14)

The kit of claim 14, wherein the at least one antibiotic is an aminoglycoside.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the at least one antibiotic is neomycin.

### Claim 17 (depends on 15)

The kit of claim 15, wherein the at least one antibiotic is kanamycin.

### Claim 18 (depends on 14)

The kit of claim 14, wherein the at least one cancer drug is cisplatin.

### Claim 19

A kit comprising: an active agent, wherein the active agent is piperlongumine, a derivative of piperlongumine, or a pharmaceutically acceptable salt thereof; and one or more of: at least one aminoglycoside antibiotic; and, instructions for preventing aminoglycoside toxicity.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the at least one aminoglycoside antibiotic is selected from the group consisting of: gentamicin, tobramycin, amikacin, neomycin, netilmicin, plazomicin, paromomycin, streptomycin and kanamycin.
